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RUNNING HEAD 
Enhancing Effect of Protamine on Activity of HGF 
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 Abstract 
Objective. The aim of the present study was to characterize the mechanism of the stimulatory 
effect of protamine on HGF activity.  
Methods. The enhancing effects of protamine on the proliferative activity of HGF were 
investigated in vivo, in primary cultured rat hepatocytes, and in perfused rat liver.  
Results. In α-naphthylisothiocyanate-intoxicated rats, pretreatment with protamine increased 
HGF-induced autophosphorylation of the HGF receptor in liver. The maximum enhancing effect 
of protamine on HGF-induced DNA synthesis of hepatocytes required a 10 minute-pretreatment 
period both in vivo and in vitro, and the stimulatory effect of protamine was not observed when 
it was administered simultaneously with HGF. Preperfusion of the liver with protamine for 10 
minutes decreased the non-saturable portion of hepatic clearance for 125I-HGF, which is mainly 
mediated by cell-surface heparan-sulfate proteoglycan (HSPG). Inhibition of HGF binding to 
heparin by protamine was confirmed using heparin-coated sepharose.  This inhibition also 
required 10 minutes of pretreatment, for protamine to bind heparin. 
Conclusion. The enhancing effect of protamine on the mitogenic activity of HGF on 
hepatocytes requires pretreatment with protamine for a short period presumably required for its 
binding to cell-surface heparin, implying possible regulation of c-met autophosphorylation by 
HSPG. 
 
KEY WORDS: Hepatocyte growth factor (HGF); Protamine; Heparin; Heparan-sulfate 
proteoglycan (HSPG)；Clearance. 
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INTRODUCTION 
   Hepatocyte growth factor (HGF), is a biologically active polypeptide with a molecular 
weight of 82-85 kD, composed of a 69 kD α-subunit and a 34 kD β-subunit (1, 2).  It is a 
potent mitogen for mature parenchymal hepatocytes (3, 4).  In addition, HGF has other 
activities such as stimulation of cell motility (5), inhibition of tumor cell growth (6) and 
proliferation of many types of epithelial cells (7-9).  In hepatic malfunctions such as partial 
hepatectomy or CCL4-induced hepatitis, HGF activity and HGF mRNA dramatically increase in 
both plasma and liver (10-12).  HGF is therefore considered to act as a hepatotropic factor in 
the repair of injured liver. 
    The biological activity of HGF is exerted through its binding to a specific receptor, a 
transmembrane tyrosine kinase that is the product of the protooncogene c-met (13,14).  The 
HGF receptor consists of an extracellular, 50 kD α chain, and a 145 kD β chain that has 
extracellular, transmembrane and intracellular regions (14).  The intracellular domain of the ß 
subunit contains a tyrosine kinase domain and sites for autophosphorylation through which the 
cellular effects of HGF receptor are mediated.  HGF binding to the receptor has been suggested 
to induce receptor dimerization, resulting in reciprocal trans-phosphorylation of each receptor 
and subsequent interaction with the other cytoplasmic effectors, through which it exerts its 
biological effects (15, 16). 
    Although HGF is expected to be clinically useful for repairing tissue injury, its systemic 
administration may be hindered by its rapid elimination from circulation (10, 11, 17, 18), which 
leads to a requirement for large amounts of repeated doses to obtain pharmacological activity 
(19).  Therefore, it is essential to develop a drug delivery system (DDS) that increases the 
efficacy of HGF mitogenic activity in vivo.  HGF binds to heparan-sulfate proteoglycan 
(HSPG), which is expressed ubiquitously on the surface of cells, and in the extracellular matrix 
(20, 21). Systemic elimination of HGF is mediated at least partially via these heparin-like 
substances, which are primarily expressed in the liver (17, 20).  Therefore, inhibition of this 
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binding may lead to stability of HGF in circulation. Recently, it was found that mutational 
deletion of the heparan sulfate binding site in HGF increases the biological activity of HGF (22, 
23), supporting the validity of this strategy. 
Finding an effective DDS for HGF may promote clinical applications of HGF.  We have 
previously demonstrated that protamine, a basic protein with an affinity for heparin, not only 
decreases the overall elimination of HGF, but also enhances the proliferative activity of HGF in 
the liver of α-naphthylisothiocyanate (ANIT)-intoxicated rats (19).  Based on these previous 
findings, coadministration of HGF with protamine may be a useful DDS for HGF that increases 
pharmacological efficacy in vivo.  However, the molecular mechanism by which protamine 
enhances HGF-induced liver regeneration is still unclear.  Protamine has been widely used as a 
carrier for gene delivery because of its potential affinity for nucleotides. Cytotoxicity exerted by 
polycationic polypeptides like protamine may be one of the stumbling blocks in the 
development of DDS. On the other hand, the use of protamine for the delivery of HGF or other 
heparin-binding proteins has not yet been reported except our approach (19). 
The aim of the present study was to characterize the enhancing effect of protamine on the 
proliferative activity of HGF. The present study revealed that protamine affects the early-phase 
of signal transduction, possibly through its activity of binding to cell-surface HSPG.  
 
MATERIALS AND METHODS  
Animals      
     Male Wistar rats weighing 240-250 g (Nisseizai, Tokyo, Japan) were used and treated in 
accordance with guidelines provided by the Institutional Animal Care Committee (Graduate 
School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan).  ANIT dissolved 
in olive oil was intraperitoneally injected at a dose of 50 mg/kg body wt. 
 
Materials 
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     Protamine sulfate purified from salmon roe was obtained from Wako Pure Chemical 
Industries, Ltd. (Osaka, Japan); ANIT, 3,3'-diaminobenzidine, Azure A and heparin were from 
Sigma (St. Louis, MO) and 125I-deoxyuridine was from New England Nuclear (Boston, MA). 
Human recombinant HGF was purified from a culture medium of C-127 cells transfected with a 
plasmid containing human HGF cDNA (24). Mouse monoclonal antibodies to phosphotyrosine 
(p-Tyr, PY20) and rabbit polyclonal antibodies to HGF receptor [m-met (SP260)] were 
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).  [125I]Anti-rabbit IgG was 
from GE Healthcare Biosciences (Buckinghamshire, UK). 
 
HGF and Protamine Injection 
   Under light ether anesthesia, HGF (300 mg/kg body wt) dissolved in saline was 
administered through the penis vein 30 min before and 8, 22, 32, 46 h after ANIT intoxication.  
Protamine (1.6 mg/kg body wt) dissolved in saline was administered 10, 30 and 120 min prior to 
the HGF injection or simultaneously administered with HGF via the same route.  In our 
previous analysis (19), the peak value of the labeling index occurred at a protamine dose of 1.6 
mg/kg, and the higher dose of protamine decreased the labeling index induced by HGF in 
ANIT-intoxicated rats. Therefore, we measured the labeling index only at 1.6 mg/kg of 
protamine in the present study.  Rats were sacrificed, and livers were excised 48 h after ANIT 
intoxication for the determination of labeling index and Western blot analysis. 
 
Measurement of Labeling Index 
     One hour before sacrifice, 5-bromo-2'-deoxyuridine dissolved in normal saline was 
intraperitoneally injected at 100 mg/kg body wt. Rats were exsanguinated via the abdominal 
artery under light ether anesthesia.  The liver was removed and fixed in 10% buffered formalin 
for 24 h.  The fixed samples were embedded in paraffin, and 4 µm paraffin sections were 
mounted on glass slides.  After deparaffinization of the liver sections, endogenous peroxidase 
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was inactivated in 0.3% hydrogen peroxide in absolute methanol, and nuclei incorporating 
5-bromo-2'-deoxyuridine were stained using a Cell Proliferation Kit (GE Healthcare 
Biosciences). The labeling index of hepatocytes was determined by counting more than 500 
nuclei from photographs of three randomly selected light microscopy fields.   
 
Assay for DNA Synthesis in Primary Cultured Rat Hepatocytes 
     Parenchymal hepatocytes were plated at a density of 1.25 x 105 cells/1.88 cm2 and 
cultured for 24 h as described previously (4).  Non-attached cells were removed by washing, 
and culture medium containing protamine applied to the monolayer.  HGF or EGF was added 
10 sec, 10 min, 30 min, 1 h and 3 h after the addition of protamine, or added simultaneously 
with protamine.  125I-deoxyuridine was added 22 h after HGF addition, and its incorporation 
after 6 h was assayed as described previously (4).  Cellular protein was determined by the 
Bradford method using Bio-Rad protein assay kits with bovine serum albumin (BSA) as a 
standard. 
 
Determination of HGF Concentration in Primary Cultured Rat Hepatocyte Medium 
After 24 hr of growth, HGF was added to primary cultures, either alone or 10 min after 
addition of 25 µg/ml of protamine. At 0, 1, 3, 6 and 24 h after HGF addition, 50 µl of medium 
was collected, and the HGF concentration (Cm) was determined by ELISA (Institute of 
Immunology Co., LTD., Tokyo, Japan). The time profile for Cm was fitted to a 
mono-exponential equation by a nonlinear iterative least squares method (17). The input data 
were weighted as the reciprocal of the square of observed values using the Damping Gauss 
Newton Method as the algorithm for fitting. The HGF clearance was calculated by dividing the 
dose applied to the medium by the area under the concentration-time curve (AUC). The AUC 
was obtained by integration of the mono-exponential equation from time 0 to infinite. 
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Liver Perfusion Experiment 
     Liver perfusion was as previously reported (11,17). In brief, 24 h after ANIT intoxication, 
single-pass perfusion was performed from rat portal veins with oxygenated perfusion buffer 
containing 3% (w/v) BSA at a perfusion rate of 30 ml/min in a temperature-controlled cabinet at 
37oC. 125I-HGF (1 µCi/ml) or 14C-taurocholate (TCA, 1 µCi/ml) with 14C or 3H-inulin (5 
µCi/ml) was injected into the portal vein as a bolus at indicated times after preperfusion with 
protamine for the indicated periods. After 30 s, the liver was excised, and radioactivity 
remaining in the liver was determined.  The hepatic extraction ratio (E) of 125I-HGF or 
14C-TCA was calculated as follows:  
EHGF = Eapp,HGF  -  Eapp,inulin              (1) 
ETCA = Eapp,TCA  -  Eapp,inulin              (2) 
where Eapp,HGF, Eapp,TCA and Eapp,inulin were the apparent extraction ratio for 125I-HGF, 14C-TCA 
and 14C-Inulin, respectively, determined by total radioactivity associated with the liver divided 
by the radioactivity injected into the portal vein. 
 
 Determination of Protamine in Plasma 
     Under light ether anesthesia, protamine (0 or 1.6 mg/kg) was administered through the 
penis vein 24 h after ANIT intoxication. Plasma was collected from the external jugular vein, 
and the protamine concentration determined using the Azure A-heparin complex method (25).  
Briefly, 400 µl of the plasma sample was added to 600 µl of assay solution containing 15 mg/ml 
of Azure A dye and 3 unit/ml of heparin dissolved in distilled water. The absorbance was then 
measured at 620 nm against the reference sample containing the same concentration of Azure A 
dye and heparin but no protamine. 
The plasma concentration (Cp) - time profiles of protamine after intravenous administration 
were fitted to the following two-exponential equation  
Cm = A exp(-αt) + B exp(-βt)                                 (3) 
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where α and β are the apparent rate constants, A and B are the corresponding zero-time 
intercepts, and t is time. The AUC was calculated as: 
AUC = A/α + B/β                                        (4)  
The half-life for β-phase was calculated as (ln 2)/β. The plasma clearance (CLplasma) and initial 
plasma concentration (C0) were calculated as Dose/AUC and the sum of A and B, respectively. 
  
 Autophosphorylation of HGF Receptor  
     At 48 h post-ANIT-intoxication, the liver was excised, homogenized and solubilized with 
lysis buffer (PBS containing 1% Triton X-100). The lysate (800 mg protein) was added to 
protein A-sepharose to remove non-specific binding, and the supernatant incubated with 
anti-HGF receptor antibody at 4 oC for 2 h, followed by further incubated with protein 
A-sepharose beads. The beads were washed three times with lysis buffer and 
immunoprecipitates boiled in Laemmli sample buffer, separated by 7.5% polyacrylamide-SDS 
gel electrophoresis and transferred to PVDF membranes (Millipore Corp., Billerica, MA). 
Membranes were blocked in Tris-buffered saline containing 5% BSA at 4oC overnight, and then 
incubated with anti-HGF receptor antibody or anti-phosphotyrosine monoclonal antibody for 3 h.  
After washing, membranes were incubated with 125I-anti-rabbit IgG for 1 h, and the densities of 
HGF receptor in phosphorylated or unphosphorylated form were detected by imaging analyzer 
(BAS III, Fujifilm, Tokyo, Japan). 
 
Binding of Protamine and HGF to Heparin Sepharose Beads 
To analyze the binding of protamine to heparin, 20 µl of heparin sepharose bead solution 
(heparin sepharose beads:PBS at 1:1) was incubated at 37oC with protamine at a final 
concentration of 0.025 - 1.0 µg/ml.  The beads were washed with ice-cold PBS, and collected 
by centrifugation.  Protamine bound to heparin sepharose beads was eluted with 20 µl of NaCl 
(1 M), and the concentration determined by the Azure A-heparin complex method (25) as 
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described above. Scatchard analysis was also performed to obtain dissociation constant (Kd) and 
maximum binding capacity (Bmax). 
To analyze the binding of HGF to heparin, 40 µl of heparin sepharose beads were 
incubated with 10 µl of HGF at a final concentration of 100-1000 µg/ml. The beads were 
washed with ice-cold PBS, and collected by centrifugation.  Bound HGF was eluted with 40 µl 
of 2 M NaCl, and HGF concentration determined by ELISA.  
  
Statistical Analysis 
     Statistical analysis was performed by a Student's t-test to identify significant differences 
between various treatment groups. 
 
RESULTS 
Effect of Protamine on HGF-Induced 
Phosphorylation of the HGF Receptor 
To characterize the enhancing effect of 
protamine on the proliferative activity of HGF, we 
first focused on phosphorylation of the HGF receptor, which is the earliest event in the signal 
transduction pathway. As per our previous in vivo analysis (19), protamine (1.6 mg/kg) was 
preinjected 10 min prior to injection of HGF.  In this study, phosphorylation of the HGF 
receptor was examined 48 h after ANIT-intoxication. Receptor phosphorylation after injection of 
HGF alone (300 µg/kg) was found to be 2.7-fold higher than the control (Fig. 1). Pretreatment 
with protamine further increased HGF receptor phosphorylation by an additional 1.5-fold, and 
protamine alone did not affect HGF receptor phosphorylation (Fig. 1). 
Fig. 1   Effect of protamine on
HGF-induced phosphorylation of
 
Effect of Protamine Pretreatment Time on HGF-Induced Proliferation In Vivo 
To determine the most suitable preinjection period for protamine, the mitogenic effect of 
HGF receptor in vivo
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HGF was examined in ANIT-intoxicated rats at various protamine preinjection times (Fig. 2).  
The labeling index of ANIT-intoxicated rat hepatocytes after administration of protamine 10 min 
prior to HGF injection was 3.3-fold than that with injection of HGF alone (Fig. 2). However, 
when protamine was simultaneously injected, or injected 30 or 120 min prior to HGF injection, 
the labeling index 
was nearly 
comparable to HGF 
alone (Fig. 2).  
Thus, the mitogenic 
effect of HGF was 
greatest after 
protamine pretreatment for 10 min prior to HGF injection. 
Fig. 3   Effect of protamine pretreatment period on the
mitogenic effect of HGF (A) and EGF (B) in primary cultured
rat hepatocytes 
 
Effect of Protamine Pretreatment Time on HGF-Induced DNA Synthesis of Hepatocytes In 
Vitro 
To further study the effect of pretreatment with protamine on HGF proliferative activity, 
DNA synthesis of HGF-treated hepatocytes in primary culture was examined after various 
protoamine pretreatment times (Fig. 3). 
Protamine was used at 25 µg/ml, since this 
concentration exerted the maximum 
stimulatory effect on HGF-induced DNA 
synthesis of hepatocytes in primary culture 
(19). When protamine was simultaneously 
added with HGF (250 pM), or added 10 sec 
prior to HGF addition, DNA synthesis was nearly the same as with HGF alone (Fig. 3A).  
However, DNA synthesis increased to 1.3 - 1.5-fold over the control level when protamine was 
Fig. 2 Effect of protamine pretreatment
period on HGF-induced liver
regeneration in ANIT-intoxicated rats
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added at 10 or 30 min, or 1 or 3 h prior to HGF addition (Fig. 3A). When the same concentration 
of HGF was added 10 min prior to protamine addition, however, DNA synthesis was 
approximately equal to that in the presence of HGF alone (Fig. 3A). Similar results were also 
observed at a lower concentration of HGF (25 pM, data not shown).  
Similar studies were also performed for EGF, another hepatocyte mitogen, since 
protamine also enhanced EGF-induced stimulation of primary hepatocyte DNA synthesis (19). 
In this case, DNA synthesis in the presence of EGF (500 pM) was higher after any protamine 
pretreatment time (Fig. 3B).  Similar results were observed at a lower EGF concentration (60 
pM, data not shown). 
 
Rapid In Vivo Disappearance of Protamine in Systemic Circulation  
Pretreatment with protamine for 30 min or 
longer increased the in vitro, but not the in vivo 
proliferative effect of HGF (Fig. 3A). One possible 
reason for this discrepancy could be rapid systemic 
elimination of protamine, so pharmacokinetic 
characterization of protamine was examined. The 
plasma concentration of protamine rapidly 
disappeared with a t1/2, and CLplasma of 9 min and 
5.3 ml/min/kg, respectively, after intravenous injection (Fig. 4). The C0 was estimated to be 24.6 
± 1.0 µg/ml, which coincided with the effective concentration of protamine that stimulated 
HGF-induced DNA synthesis of hepatocytes in vitro (19). The plasma protamine concentration 
decreased to 10.2 ± 0.2 µg/ml at 10 min after injection (Fig. 4). This concentration of protamine 
could not enhance HGF-induced DNA synthesis in primary cultured hepatocytes (19). 
Fig. 4    Elimination profile of
protamine after intravenous
administration in rats 
 
Effect of Protamine Pretreatment on Low-Affinity Clearance Sites for 125I-HGF in 
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Perfused Rat Liver 
To further characterize 
the effect of protamine 
pretreatment on hepatic 
processing of HGF, we 
determined the change in hepatic 
clearance of HGF, assessed as EHGF of 125I-HGF in perfused rat liver, at varying pretreatment 
times with a constant amount of perfused protamine (Fig. 5A). With 1 or 3 min pretreatment 
periods, the EHGF of 125I-HGF was nearly comparable with the control (Fig. 5A). However, when 
the pretreatment period was increased to 5, 7 or 10 min, the EHGF value decreased in a manner 
dependent on the pretreatment period (Fig. 5A). The ETCA was almost unchanged with 
protamine pretreatment under the same conditions (Fig. 5B). Pretreatment with protamine at 25, 
36, 50 and 83 µg/ml for 1 min gave an EHGF almost equal to the control (data not shown). 
Fig. 5   Effect of protamine preperfusion period on 
hepatic extraction ratio of 125I-HGF (A) and 14C-TCA 
(B) 
Association of HGF on hepatocytes is mediated by high-affinity and low-affinity 
clearance sites, which are presumably mediated by the HGF receptor and a heparin-like 
substance, respectively (17). To examine the effect of protamine pretreatment on these two sites 
separately, EHGF was measured in the presence of excess unlabeled HGF (500 pM), sufficient to 
saturate the high-affinity site (17) (Table 1). The EHGF value in the absence of unlabeled HGF 
decreased after 10 min of pretreatment with protamine (25 µg/ml) (Table 1). A similar effect for 
protamine preperfusion was observed for the EHGF in the presence of unlabeled HGF (500 pM), 
but was not seen for the specific extraction of 125I-HGF obtained by subtracting EHGF in the 
presence of unlabeled HGF from EHGF in its absence (Table 1). Thus, the effect of protamine 
pretreatment was more apparent on association of HGF with the low-affinity binding site. 
 
Table 1. Effect of Protamine on Hepatic Extraction of 125I-HGF in Perfused Rat Livera)      
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 HGF          Protamine          EHGFb)           ETCAb)
concentration     concentration 
 (µg/ml)         %               %  
                                       (Mean ± SEM)    (Mean ± SEM) 
 
Tracer 125I-HGF alone  0      43.7±1.0     89.6 ± 1. 1  
                                      
                 25       30.9±1.4     87.0 ± 3.3 
 
 Tracer 125I-HGF     0      14.9±0.6     88.6 ± 3.1    
+    
 500 pM HGFc)       25      6.40±0.3     85.4 ± 3.6 
 
 Specific extractiond)        0        28.8±1.5  
                                      
                         25      24.5±1.1  
 
a) During a single-pass perfusion of ANIT-intoxicated rat liver, 125I-HGF or 14C-TCA was injected into 
the portal vein just after preperfusion with protamine for 10 min, followed by determination of 
radioactivity remaining in the liver 30 sec later.  
b) The hepatic extraction ratio of 125I-HGF and 14C-TCA was calculated by Eqs. (1) and (2), respectively. 
c) Unlabeled HGF (500 pM) was co-perfused for 1 min before the radioactivity determination. 
d) Specific extraction was obtained by subtracting the EHGF of 125I-HGF in the presence of unlabeled HGF, 
from the EHGF in its absence. 
 
Effect of Protamine on Binding of HGF to Heparin 
The effect of protamine on the association of HGF with the low-affinity binding site (Table 
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1) may imply an inhibitory effect of protamine on HGF binding with HSPG on the liver 
cell-surface. To investigate the effect of 
protamine on HGF binding to heparin, 
the binding characteristics of protamine 
itself to heparin (Fig. 6A, 6B), and the 
effect of protamine on HGF binding to 
heparin (Fig. 6C), were examined using 
heparin sepharose beads. The amount of 
protamine binding to heparin sepharose 
beads increased in a time-dependent 
manner from 0.25 to 10 min, with 
maximum binding observed at 10 min (Fig. 6A). After 10 min, the binding of protamine 
plateaued (Fig. 6A). Binding of protamine to heparin was further characterized by Scatchard 
plot analysis (Fig. 6B). The Kd and Bmax were 1.00 µM and 24.0 nmol/ml beads, respectively 
(Fig. 6B).  
Fig. 6   Binding of protamine (A, B) or HGF
(D) to heparin and inhibition by protamine of
HGF binding to heparin (C) 
HGF also binds to heparin sepharose beads, and binding reached maxmimal levels 
within 2 min (Fig. 6C). A similar binding pattern was also found when both HGF and protamine 
were simultaneously added to heparin sepharose beads (Fig. 6C),but when protamine was added 
10 min prior to HGF addition, the binding of HGF decreased to 30 - 50% of the control level, 
and the binding reached a plateau within 10 min (Fig. 6C). Binding of HGF to heparin was 
further characterized by Scatchard plot analysis, yielding Kd and Bmax values of 1.11 nM and 
0.145 pmol/ml beads, respectively (Fig. 6D). 
 
Protamine increases the maximum HGF-induction of primary hepatocyte proliferation 
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The enhancing effect of protamine on HGF-induced DNA synthesis of hepatocytes (19) 
might be explained at least in part by the inhibition of hepatocellular clearance of HGF by 
protamine. In the present study, to separately estimate the effect of protamine on the mitogenic 
effect and the clearance of HGF, both the DNA synthesis of hepatocytes in primary culture and 
the HGF concentration profile in the medium were measured (Fig. 7). HGF in the medium 
gradually disappeared, and protamine (25 µg/ml) hindered this disappearance (Fig. 7A). The 
HGF clearances were 23.0 ± 4.6 and 5.81 ± 2.30 nl/min/mg protein in the absence and presence 
of protamine, respectively (Fig. 7A). These values corresponded to 27.7 and 15.1 ml/min/kg 
body wt, if we assume that 1 g liver corresponds to 118 mg protein, 1 kg body wt includes 40 g 
liver, and the hepatic plasma flow rate equals 36.4 ml/min/kg body wt (26, 27). These 
extrapolated values were close to the observed values for plasma clearance of HGF (32.1 and 
12.7 ml/min/kg in the absence and presence of protamine, respectively) (19). DNA synthesis in 
the presence of HGF, with or without protamine pretreatment, was then measured and plotted 
against AUC of HGF in medium, to avoid the effect of protamine on HGF clearance (Fig. 7B). 
In the absence of protamine, DNA synthesis reached nearly the maximum value at 250 pM of 
HGF (Fig. 7B). In the presence of protamine, DNA synthesis with 25 - 1,000 pM of HGF was 
higher than that in the 
absence of protamine (Fig. 
7B). The enhancing effect of 
protamine was more 
apparent for DNA synthesis 
induced by higher 
concentrations of HGF (250 
- 1,000 pM), whereas the protamine effect on DNA synthesis induced by 25 pM HGF could be 
almost fully explained by the inhibition of HGF clearance, since DNA synthesis at 25 pM HGF 
with protamine was superimposable on the line obtained in the absence of HGF (Fig.7B).  
Fig. 7   Effect of protamine on HGF
DNA s
 elimination and HGF-induced 
ynthesis in rat hepatocytes
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 DISCUSSION 
HGF exerts mitogenic, morphogenic and motogenic activities in various types of cells 
(28, 29).  These physiological activities are all initially mediated by c-met tyrosine kinase, the 
receptor for HGF (13).  In the present study we found that protamine preinjection significantly 
enhanced the effect of HGF on phosphorylation of the HGF receptor, and protamine alone did 
not stimulate phosphorylation (Fig.1). Protamine pretreatment did not enhance the amount of 
HGF receptor, according to Western blot analysis using anti-HGF receptor antibody (data not 
shown). These results suggest that the effect of protamine could be relevant to the early-phase 
event in signal transduction from the HGF receptor. We have previously reported that protamine 
enhances the proliferative activity of HGF on hepatocytes (19). This enhancement could be 
explained at least in part by protamine stimulation of HGF-induced receptor phosphorylation 
(Fig. 1). 
Since the effect of protamine is relevant to this early-phase event, we determined the 
length of protamine pretreatment that was required to stimulate the proliferative activity of HGF. 
Protamine pretreatment periods from 0 to 120 min were tested (Fig. 2). In vivo, the enhancing 
effect of protamine on HGF-induced liver regeneration depended strongly on the protamine 
pretreatment period (Fig. 2). The pretreatment period with protamine for 10 min seems to be 
essential for the enhancing effect of protamine on the proliferative activity of HGF (Fig. 2). This 
was, in principle, consistent with the observations of HGF-induced DNA synthesis in primary 
cultured hepatocytes, although the protamine effect in primary cultures was maintained for over 
30 min prior to HGF addition (Fig. 3A). 
The unique characteristics of the protamine effect prompt questions about the possible 
reasons for such a strict preincubation period. Some answers are provided by the profile of 
plasma protamine concentration over time, after intravenous injection into ANIT-intoxicated rats. 
The C0 of protamine was found to be 25 µg/ml, falling to 10 µg/ml just 10 min after intravenous 
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injection (Fig. 4). According to our previous analysis with primary cultured rat hepatocytes, 
HGF-induced DNA synthesis was enhanced by 25 µg/ml, but not by 6 - 12.5 µg/ml of protamine 
(19). Thus, effective protamine concentration in circulating plasma for enhancing HGF activity 
was maintained for only approximately 10 min after intravenous injection in vivo (Fig. 4). This 
could be the reason for the minimal enhancement of protamine on HGF activity in vivo when the 
pretreatment period was 30 min or longer (Fig. 1). The protamine concentration in cultured 
hepatocyte medium could be maintained for a longer period than in vivo, explaining why 
enhancing effects of protamine were observed with pretreatment periods of 30 min or longer 
(Fig. 3A). 
The strict period of approximately 10 min of protamine pretreatment may also be 
relevant to the time required for protamine to bind to heparin.  Protamine is a basic protein and 
binds to heparin (30). In the present study, the preperfusion effect of protamine was also 
observed on EHGF (Fig. 5A) and more pronounced when EHGF was measured in the presence of 
excess unlabeled HGF (Table 1), suggesting that protamine mainly inhibits low-affinity HGF 
binding on the liver cell-surface. Since the high- and low-affinity binding sites for HGF on liver 
cells mainly represent HGF receptor and HSPG, respectively (17), protamine mainly inhibits the 
binding of HGF to HSPG. In fact, we demonstrated that protamine binds to heparin (Figs. 6A, 
6B) and inhibits the binding of HGF to heparin (Fig. 6C). Interestingly, approximately 10 
minutes was necessary for maximum binding of protamine to heparin (Fig. 6A). This coincided 
with the time required for the maximum stimulatory effect of protamine on HGF proliferative 
effects in vivo (Fig. 2) and in vitro (Fig. 3), and the maximum inhibitory effect of protamine on 
hepatic extraction of HGF (Fig. 5A). In addition, simultaneous addition of protamine with HGF 
minimally affected the binding of HGF to heparin (Fig. 6C), and consistent with the finding that 
simultaneous addition of protamine with HGF did not increase the proliferative activity of HGF 
in vivo (Fig. 2) or in vitro (Fig. 3). According to these results, 10 min may be required for 
protamine to occupy HSPG on cell-surfaces and inhibit HGF binding. On the other hand, HGF 
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is also a basic protein and has an affinity for heparin (31, 32). HGF can bind to heparin sulfate 
expressed on the surface of ubiquitous cells and in the extracellular matrix (20, 21). In the 
present study HGF bound to heparin more rapidly than protamine (Figs. 6A, 6C).  Compared 
with HGF, protamine had a much lower affinity for heparin, with a 1000-fold difference in Kd 
between the two proteins (Fig. 6B, 6D). This may explain why the enhancing effect of 
protamine was almost completely abolished when protamine and HGF were simultaneously 
injected or added (Figs. 2, 3A). 
We previously proposed that the combination of HGF and protamine may provide an 
adequate DDS for HGF, enhancing the proliferative activity of HGF and decreasing its systemic 
clearance (19). Although HGF is expected to be clinically useful for repairing tissue injury, rapid 
elimination of HGF from circulation may hinder clinical applications. Binding HSPG with 
protamine may be a rational strategy for inhibiting the HSPG-mediated HGF elimination 
pathway (19). However, considering the present findings, strict control over the timing of 
sequential administration of protamine and HGF may be required for optimal pharmacological 
efficacy. In addition, the labeling index occurred at a protamine dose higher than 1.6 mg/kg was 
decreased in ANIT-intoxicated rats in vivo, and HGF-induced DNA synthesis in primary 
cultured hepatocytes in vitro was decreased in the presence of 50-200 µg/ml of protamine, both 
of these findings being probably due to the cytotoxicity exerted by protamine (19). Existence of 
such optimal dose and/or concentration of protamine may also complicate the application of 
protamine to DDS. Alternatively, it may be important to find proteins other than protamine that 
have a much higher affinity for heparin, and can more strongly stimulate the proliferative 
activity of HGF. 
In the present study, we found that protamine delayed the elimination of HGF from the 
medium of primary cultured hepatocytes (Fig. 7A, 7B), confirming the previous in vivo finding 
(19). At 25 pM HGF, the enhancing effect of protamine on HGF-induced DNA synthesis might 
be explained by the increase in AUC of HGF, since the data for DNA synthesis in the presence 
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of protamine was almost superimposable on the data for HGF alone (Fig. 7B). The mitogenic 
effect of HGF alone reached maximum value at 250 pM HGF (Fig. 7B). On the other hand, 
when protamine was added prior to HGF, the maximum DNA synthesis increased further, and 
this could not be explained by an increase in AUC (Fig. 7B). Thus, the stimulating effect of 
protamine was much more apparent at higher HGF concentrations (>250 pM), in which the 
HGF receptor is completely occupied, according to the 20 - 40 pM dissociation constant of HGF 
to HGF receptor. On the other hand, preperfusion with protamine mainly affected the 
low-affinity site for HGF (Table 1), suggesting that protamine mainly interacts with heparin. 
Naka et al. (33) and Schwall et al. (34) proposed that the mitogenic activity of HGF on 
hepatocytes is regulated by HSPG. Protamine might first bind to cell-surface heparin, affecting 
signal transduction between heparin and the HGF receptor at the cell-surface, and leading to 
stimulation of HGF receptor autophosphorylation (Fig. 1). Several recent studies have shown 
that, upon tyrosine kinase phosphorylation, the HGF receptor is associated with a number of 
SH2-containing signal mediators, such as the Ras GTPase-activation protein, the p85 subunit of 
phosphatidylinositol (PI) 3-kinase, phospholipase C (PLC) γ1, and a cytoplasmic tyrosine kinase 
of the Src family (35-37).  PLCγ1 is also reported to mediate an intracellular signal for the 
HGF-enhanced mitogenesis of primary cultured rat hepatocytes (38).  Whether the enhancing 
effect of protamine on HGF-induced liver regeneration is also related to these mediators remains 
to be elucidated. 
EGF is another hepatocyte mitogen (39). Until now, an affinity of EGF for heparin has 
not been found. Lokeshwar et al. (40) reported that, in Swiss 3T3 cells and human epidermoid 
carcinoma A431, protamine induced an increase in the number of EGF receptors, which are also 
transmembrane tyrosine protein kinase receptors, by activating cryptic or inactive receptors to 
functionality.  This may be relevant to our finding that the enhancing effect of protamine on 
EGF-induced DNA synthesis was not dependent on the timing of addition of protamine (Fig. 
3B).  
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CONCLUSION 
Protamine enhances HGF-induced phosphorylation of the HGF receptor, possibly by 
inhibiting the binding of HGF to a heparin-binding substance on the cell-surface. The protamine 
effect requires approximately 10 min of pretreatment, because of its relatively low affinity for 
heparin. 
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 Figure Legends 
Figure 1.   Effect of protamine on HGF-induced phosphorylation of HGF receptor in 
vivo. 
     Saline (C), protamine (1.6 mg/kg) (P), HGF (300 µg/kg) (H) or HGF (300 µg/kg) with 
protamine (1.6 mg/kg at 10 min prior to HGF injection) (H+P) was intravenously administered 
in ANIT-intoxicated rats, and livers homogenized 48 h after ANIT-intoxication.  
Phosphorylation of the HGF receptor was detected by immunoprecipitation with anti-HGF 
receptor antibody and subsequent western blot analysis using anti-phosporylated tyrosine 
antibody.  The left panel represents a typical western blot, with relative band densities (% of 
control) shown in the right panel, in which each value and vertical bar represents the mean ± 
SEM of three determinations.   
*: Significantly different from HGF alone (p < 0.05). 
 
Figure 2.  Effect of protamine pretreatment period on HGF-induced liver regeneration in 
ANIT-intoxicated rats. 
      In ANIT-intoxicated rats, protamine (1.6 mg/kg) was intraveously administered alone, or 
at the indicated minutes prior to injection of HGF (300 µg/kg). The labeling index of 
hepatocytes was determined 48 h after ANIT intoxication. ANIT(+) and ANIT(-) represent 
ANIT-intoxicated rats, and non-intoxicated rats treated with saline.  Each value and vertical bar 
represents the mean ± SEM of 3 - 5 rats.   
**: Significantly different from HGF alone (p < 0.01). 
 
Figure 3.   Effect of protamine pretreatment period on the mitogenic effect of HGF (A) 
and EGF (B) in primary cultured rat hepatocytes. 
Parenchymal hepatocytes were cultured for 24 h, and HGF (250 pM) (A) or EGF (500 
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pM) (B) added at the indicated time periods after the addition of protamine (25 µg/ml).  DNA 
synthesis was assayed as incorporation of 125I-deoxyuridine from 22 to 28 h after HGF addition. 
The right-most sidebar in each panel shows the results of addition of HGF or EGF at 10 min 
prior to protamine addition.  Each value and vertical bar represents the mean ± SEM of 3 - 5 
rats.   
*: Significantly different from HGF alone (p < 0.05). 
 
Figure 4.  Elimination profile of protamine after intravenous administration in rats. 
At 24 h after ANIT-intoxication, protamine (1.6 mg/kg) was intravenously given, and the 
concentration of protamine in plasma determined by Azure A-heparin complex method. Each 
value and vertical bar represents the mean ± SEM of 3 - 5 rats. 
 
Figure 5.  Effect of protamine preperfusion period on hepatic extraction ratio of 125I-HGF 
(A) and 14C-TCA (B). 
After preperfusion with protamine at the indicated concentrations for the indicated time 
period, 125I-HGF (0.2 µCi/0.2 ml/liver) (A) and 14C-TCA (0.2 µCi/0.2 ml/liver) (B) were 
injected into the portal vein as a bolus, followed by resection of the liver after 30 sec.  
Radioactivity in the excised liver was determined and normalized by dose.  Data represent 
means ± SEM of 3 - 5 rats.   
* and **: Significantly different from control (p < 0.05 and 0.01, respectively). 
 
Figure 6.  Binding of protamine (A, B) or HGF (D) to heparin and inhibition by 
protamine of HGF binding to heparin (C). 
In panel A, 20 µL of heparin- sepharose beads were incubated with 500 µg/ml of protamine at 
37oC for the indicated period, and binding of protamine was determined. In panel B, the same 
amount of heparin sepharose beads was incubated with protamine (0.025 - 1.0 mg/ml) at 37oC 
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for 30 min, and the binding of protamine shown as a Scatchard plot. In panel C, 40 µl of heparin 
sepharose beads were incubated with HGF (500 µg/ml) alone (●), with protamine 
simultaneously added (○) or protamine added 10 min prior to HGF addition (■), followed by 
ELISA determination of bound HGF. In panel D, 40 µl of heparin sepharose beads were 
incubated with 10 µl of HGF at final concentrations of 100-1000 µg/ml, and the binding of HGF 
shown as a Scatchard plot.  Data represent mean ± SEM of 3 independent experiments. 
 
Figure 7. Effect of protamine on HGF elimination and HGF-induced DNA synthesis in rat 
hepatocytes. 
Parenchymal rat hepatocytes were cultured for 24 h. Protamine at 0 (○) or 25 (●) µg/ml 
was added 10 min prior to addition of HGF. In panel A, HGF concentration in the medium was 
determined by ELISA after the addition of 250 pM HGF.  Data represent means ± SEM of 3 - 5 
rats. In panel B, 50 µl of medium was collected at 0, 1, 3, 6 and 24 h after addition of various 
concentrations of HGF to determine AUC values. 125I-deoxyuridine was added at 22 h after 
addition of HGF, and its incorporation for 6 h was assayed as DNA synthesis, shown plotted 
against AUC of HGF. Data represent means ± SE of 3 - 5 rats. 
**: Significantly different from control (p < 0.01).  
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